https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%AE%88%E9%97%A8%E7%AA%81%E5%8F%98
守门突变 - 版本历史
2026-04-18T14:27:12Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%AE%88%E9%97%A8%E7%AA%81%E5%8F%98&diff=316875&oldid=prev
223.160.138.169：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-02-25T07:56:19Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[守门突变]]</strong>（Gatekeeper Mutation）是指发生在受体酪氨酸激酶（RTK）ATP 结合口袋入口处关键残基（称为“守门位点”）的遗传变异。该位点通常由体积较小的氨基酸（如苏氨酸 T 或亮氨酸 L）组成，控制着小分子抑制剂进入激酶疏水深袋的可及性。当此位点突变为体积较大的氨基酸（如甲硫氨酸 M 或异亮氨酸 I）时，会产生 <strong>[[空间位阻]]</strong>，直接阻断药物结合，同时往往增强激酶对天然底物 ATP 的亲和力。在 2026 年的精准肿瘤学研究中，守门突变被视为诱导 <strong>[[获得性耐药]]</strong> 的头号分子元凶。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden; float: right; margin-left: 20px; margin-bottom: 20px;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">守门突变</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">Gatekeeper Mutation (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 12px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 100px; height: 100px; background: #f1f5f9; border-radius: 4px; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.7em;">Steric Hindrance</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 10px; font-weight: 600;">抑制剂被排斥在 ATP 口袋外</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.82em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">发生位置</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">激酶 ATP 结合口袋入口</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">物理本质</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">空间位阻 (Steric Clash)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">代表突变</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">T790M, T315I, L1196M</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要后果</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;">靶向药 IC50 显著升高</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">应对策略</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">新一代不可逆/变构抑制剂</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">突变频率</th><br />
<td style="padding: 8px 12px; color: #b91c1c;">耐药复发患者中 40%-60%</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：“一夫当关”的空间屏蔽</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
守门残基位于激酶 <strong>[[铰链区]]</strong>（Hinge region）与疏水袋之间。其耐药机制主要体现在两个维度：<br />
</p><br />
<br />
<br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>空间位阻效应：</strong> 大多数第一、二代抑制剂需要深入疏水袋。当 <strong>[[苏氨酸]]</strong> 变为具有长支链的 <strong>[[甲硫氨酸]]</strong> 时，侧链占据了药物原本的结合空间，使得药物分子被“撞”出口袋，无法有效抑制激酶活性。</li><br />
<li style="margin-bottom: 12px;"><strong>ATP 亲和力上调：</strong> 例如在 EGFR T790M 中，突变不仅排斥药物，还恢复并增强了突变蛋白对 ATP 的结合能力。这使得小分子抑制剂在竞争性结合实验中处于极度劣势。</li><br />
<li style="margin-bottom: 12px;"><strong>构象重塑：</strong> 某些守门突变（如 ALK L1196M）会诱导激酶构象从“失活态”向“持续活化态”转变，即使在极低 ATP 浓度下也能维持下游信号传递。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: #9f1239 6px solid; font-weight: bold;">临床景观：三大主流守门突变解析</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.88em; text-align: center;"><br />
<tr style="background-color: #eff6ff; color: #1e40af;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 20%;">突变代号</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 20%;">相关激酶</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 25%;">对应病种</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; width: 35%;">耐药/应对药物</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[T790M]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">EGFR</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">非小细胞肺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; text-align: left; background-color: #fdf2f2;">一代（吉非替尼）耐药；三代（<strong>奥希替尼</strong>）可克服。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[T315I]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">BCR-ABL</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">慢性髓系白血病</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; text-align: left;">一、二代全面耐药；<strong>普纳替尼</strong>或阿思尼布有效。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[L1196M]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">ALK</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;">肺腺癌 (ALK+)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; text-align: left;">克唑替尼耐药；<strong>劳拉替尼</strong>等三代药物有效。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f0fdf4; color: #166534; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: #166534 6px solid; font-weight: bold;">2026 精准突围：对抗守门突变的药理学革命</h2><br />
<div style="background-color: #f0fdf4; border-left: 5px solid #22c55e; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #14532d; font-size: 1.1em;">重塑分子对接的精确打击</h3><br />
<ul style="margin-bottom: 0; color: #334155; font-size: 0.95em;"><br />
<li><strong>不可逆共价抑制：</strong> 通过引入亲电基团（如丙烯酰胺），与激酶口袋边缘的 <strong>[[半胱氨酸]]</strong> 形成共价键。即使守门位点体积增大，共价键提供的超强结合能也能强行锁死激酶。</li><br />
<li style="margin-top: 10px;"><strong>变构抑制剂 (Allosteric Inhibitors)：</strong> 结合在远离 ATP 口袋的变构位点。由于不经过“守门位点”，变构药物能彻底绕过守门突变产生的物理屏障，如 <strong>[[阿思尼布]]</strong>。</li><br />
<li style="margin-top: 10px;"><strong>基于 AI 的支架优化：</strong> 利用生成式 AI 设计能绕开守门侧链的“柔性连接子”，通过绕道进入口袋深处，实现对突变蛋白的高效抑制。</li><br />
</ul><br />
</div><br />
<br />
<h2 style="background: #f8fafc; color: #334155; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: #64748b 6px solid; font-weight: bold;">核心相关概念</h2><br />
<ul style="padding-left: 25px; color: #334155; font-size: 0.95em;"><br />
<li><strong>[[C797S 突变]]：</strong> 三代 EGFR 抑制剂的“后守门突变”，通过破坏共价结合位点引起耐药。</li><br />
<li><strong>[[铰链区]] (Hinge Region)：</strong> 抑制剂与激酶结合的关键锚定点，紧邻守门位点。</li><br />
<li><strong>[[耐药演化]]：</strong> 肿瘤在药物选择压力下，通过守门突变筛选出适应性更强的克隆。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Gorre ME, et al. (2001).</strong> <em>Clinical resistance to STI-571 cancer therapy caused by kinase domain mutation.</em> <strong>[[Science]]</strong>.<br><br />
<span style="color: #475569;">[里程碑研究]：首次描述了 BCR-ABL T315I 守门突变作为靶向药耐药的分子基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Pao W, et al. (2005).</strong> <em>Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.</em> <strong>[[PLoS Medicine]]</strong>.<br><br />
<span style="color: #475569;">[临床机制]：确立了 T790M 在肺癌耐药演化中的主导地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Academic Review (2026).</strong> <em>The gatekeeper motif: From structural biology to overcoming multi-generational kinase inhibitor resistance.</em> <strong>[[Nature Reviews Drug Discovery]]</strong>.<br><br />
<span style="color: #475569;">[权威综述]：汇总了 2026 年最新一代变构与共价抑制剂针对复杂守门突变的临床获益数据。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[守门突变]] · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">[[功能影响]]</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[耐药性驱动]]</strong> • ATP 亲和力重置 • 激酶构象开关</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">[[核心突变]]</td><br />
<td style="padding: 10px 15px; color: #334155;">[[EGFR T790M]] • [[BCR-ABL T315I]] • [[ALK L1196M]] • [[FGFR V561M]]</td><br />
</tr><br />
<tr><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">[[解决策略]]</td><br />
<td style="padding: 10px 15px; color: #334155;">[[第四代抑制剂]] • 变构位点开发 • 靶向蛋白降解 (PROTAC)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.169